Title (en)

CRYSTALLINE POLYMORPHS OF A CXC-CHEMOKINE RECEPTOR LIGAND

Title (de)

KRISTALLINE POLYMORPHE EINES CXC-CHEMOKINREZEPTORLIGANDEN

Title (fr)

POLYMORPHES CRISTALLINS D'UN LIGAND DU RECEPTEUR DES CXC-CHIMIOKINES

Publication

EP 1723131 B1 20100818 (EN)

Application

EP 05712748 A 20050128

Priority

- US 2005003414 W 20050128
- US 54048704 P 20040130

Abstract (en)

[origin: WO2005075447A1] The present invention relates to four distinct crystalline polymorphs of a monohydrate of Compound A having the following chemical structure (A). These four polymorphic forms, herein referred to as Forms I, II, III and IV are active as a CXC-chemokine receptor ligands. The invention is further directed to formulations, methods of treatment, and processes of synthesis of these polymorphic forms.

IPC 8 full level

C07D 307/52 (2006.01); **A61K 31/34** (2006.01); **A61K 31/341** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP KR US)

A61K 31/341 (2013.01 - KR); **A61P 1/02** (2017.12 - EP); **A61P 1/04** (2017.12 - EP); **A61P 1/16** (2017.12 - EP); **A61P 1/18** (2017.12 - EP); **A61P 3/02** (2017.12 - EP); **A61P 7/00** (2017.12 - EP); **A61P 7/02** (2017.12 - EP); **A61P 7/06** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 9/12** (2017.12 - EP); **A61P 9/14** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 11/14** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 15/00** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/02** (2017.12 - EP); **A61P 17/04** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 17/10** (2017.12 - EP); **A61P 19/00** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 19/06** (2017.12 - EP); **A61P 19/10** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/04** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 27/02** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/04** (2017.12 - EP); **A61P 31/12** (2017.12 - EP); **A61P 31/18** (2017.12 - EP); **A61P 31/22** (2017.12 - EP); **A61P 33/06** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **C07D 307/52** (2013.01 - EP KR US)

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA HR LV MK YU

DOCDB simple family (publication)

WO 2005075447 A1 20050818; AR 047739 A1 20060215; AT E478061 T1 20100915; AU 2005210504 A1 20050818; AU 2005210504 B2 20090108; BR PI0507329 A 20070703; CA 2554709 A1 20050818; CA 2554709 C 20111115; CN 1914187 A 20070214; CN 1914187 B 20120125; CO 5700731 A2 20061130; DE 602005022986 D1 20100930; EC SP066733 A 20061124; EP 1723131 A1 20061122; EP 1723131 B1 20100818; ES 2349788 T3 20110111; HK 1091496 A1 20070119; IL 177033 A0 20061210; JP 2007519751 A 20070719; JP 2011042692 A 20110303; KR 100883476 B1 20090216; KR 20060128981 A 20061214; MX PA06008599 A 20060828; MY 144657 A 20111031; NO 20063841 L 20061027; NZ 548499 A 20100625; PE 20051093 A1 20060116; PL 380997 A1 20070416; RU 2006131050 A 20080310; RU 2388756 C2 20100510; TW 200536848 A 20051116; US 2005192345 A1 20050901; US 2008279822 A1 20081113; US 8207221 B2 20120626; ZA 200606295 B 20080227

DOCDB simple family (application)

US 2005003414 W 20050128; AR P050100328 A 20050128; AT 05712748 T 20050128; AU 2005210504 A 20050128; BR PI0507329 A 20050128; CA 2554709 A 20050128; CN 200580003507 A 20050128; CO 06072748 A 20060725; DE 602005022986 T 20050128; EC SP066733 A 20060728; EP 05712748 A 20050128; ES 05712748 T 20050128; HK 06113165 A 20061130; IL 17703306 A 20060723; JP 2006551613 A 20050128; JP 2010267895 A 20101130; KR 20067015429 A 20060728; MX PA06008599 A 20050128; MY PI20050328 A 20050128; NO 20063841 A 20060829; NZ 54849905 A 20050128; PE 2005000105 A 20050128; PL 38099705 A 20050128; RU 2006131050 A 20050128; TW 94102703 A 20050128; US 17447008 A 20080716; US 4577205 A 20050128; ZA 200606295 A 20060728